In April 2018 a video describing the DAVIAD project was uploaded to the EU Science & Innovation playlist on YouTube. This video features Prof David Wraith (Apitope Chief Scientific Officer) who discusses the development of a new disease modifying therapy, that could lead to the first new line of treatment for Graves’ Disease in a generation, and Janis Hickey (Founder of the British Thyroid Foundation) who describes the effects of living with Graves’ Disease from a patient’s perspective.

To promote the study awareness within the patient community, the Daviad clinical study has been described in the British Thyroid Foundation February 2017 newsletter. Information is provided on how a patient may participate in the clinical trial and the location of the UK research study centres.

To promote awareness within the GP community, the Daviad clinical study has been briefly described in the February edition of the Royal College of General Practitioners February 2017 newsletter. A web-link is provided to the British Thyroid Foundation website where more information is available on the clinical trial and the location of the UK research…

Apitope announces the enrolment of first patient in the Phase I trial of ATX-GD-59 for the treatment of Graves’ disease. You can view the full press release available here. For further details of the trial and recruitment please visit Apitope Clinical Trials.

Apitope and the DAVIAD project have been featured in the British Thyroid Foundations newsletter N°92. In newsletter 92, the British Thyroid Foundation reported regulatory approval and planned recruitment of patients. For further information please visit the British Thyroid Foundation website: http://www.btf-thyroid.org/

Diepenbeek, Belgium – July 2016 – The July 2016 version of the newsletter provides an update on Apitope’s first clinical trial in patients with Graves’ disease and is now available to members of the British Thyroid Foundation.

Newcastle, UK – May 12th-13th 2016 – This commemorative meeting, partly sponsored by Apitope International NV, marks the 125th anniversary of the discovery of thyroid hormone replacement therapy and consists of an international panel of speakers from the thyroid autoimmunity and ophthalmology…

Cardiff University, UK – April 21st – 22nd 2016 – INDIGOs main objective is to improve management of Graves’ orbitopathy , a distressing eye condition which affects more than 3 million people in Europe. The symposium, partly sponsored by Apitope International NV, consists of an international panel of speakers from the thyroid autoimmunity and ophthalmology communities…